APP and cerebral small vessel disease: To test our hypotheses, we used a transgenic rat model that expresses APP and PS1 mutations but also has cerebral small vessel disease (chronic hypertension-driven cerebrovascular small vessel disease, a prevalent co-morbidity, that accelerates tauopathy in the model [24, 25]).